Grace Therapeutics Inc (GRCE)
3.125
+0.02
(+0.81%)
USD |
NASDAQ |
Oct 31, 16:00
3.15
+0.02
(+0.80%)
After-Hours: 20:00
Grace Therapeutics Net Income (Quarterly): -2.617M for June 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -2.617M |
| March 31, 2024 | -3.166M |
| December 31, 2023 | -2.391M |
| September 30, 2023 | -3.273M |
| June 30, 2023 | -4.023M |
| March 31, 2023 | -29.09M |
| December 31, 2022 | -3.889M |
| September 30, 2022 | -4.929M |
| June 30, 2022 | -4.524M |
| March 31, 2022 | -3.904M |
| December 31, 2021 | -3.778M |
| September 30, 2021 | 0.981M |
| June 30, 2021 | -3.118M |
| March 31, 2021 | -5.646M |
| December 31, 2020 | -3.22M |
| September 30, 2020 | -6.146M |
| June 30, 2020 | -4.666M |
| March 31, 2020 | 16.62M |
| December 31, 2019 | -12.12M |
| September 30, 2019 | -21.16M |
| June 30, 2019 | -8.846M |
| March 31, 2019 | -13.85M |
| December 31, 2018 | -3.385M |
| September 30, 2018 | -17.59M |
| June 30, 2018 | -5.642M |
| Date | Value |
|---|---|
| March 31, 2018 | -6.024M |
| December 31, 2017 | -4.834M |
| September 30, 2017 | -3.633M |
| June 30, 2017 | -2.136M |
| November 30, 2016 | -1.784M |
| August 31, 2016 | -1.779M |
| May 31, 2016 | -2.418M |
| February 29, 2016 | -1.373M |
| November 30, 2015 | -1.639M |
| August 31, 2015 | -0.9369M |
| May 31, 2015 | -0.7771M |
| February 28, 2015 | -1.895M |
| November 30, 2014 | 2.629M |
| August 31, 2014 | -3.414M |
| May 31, 2014 | 1.250M |
| February 28, 2014 | -1.903M |
| November 30, 2013 | -3.632M |
| August 31, 2013 | -3.072M |
| May 31, 2013 | -1.907M |
| February 28, 2013 | -1.760M |
| November 30, 2012 | -1.622M |
| August 31, 2012 | -1.765M |
| May 31, 2012 | -1.529M |
| February 29, 2012 | -1.741M |
| November 30, 2011 | -2.137M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-29.09M
Minimum
Mar 2023
16.62M
Maximum
Mar 2020
-4.363M
Average
-3.889M
Median
Dec 2022
Net Income (Quarterly) Benchmarks
| Aurinia Pharmaceuticals Inc | 0.722M |
| Edesa Biotech Inc | -1.668M |
| Lexaria Bioscience Corp | -1.782M |
| Xenon Pharmaceuticals Inc | -57.92M |
| ESSA Pharma Inc | -7.234M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 4.963M |
| EPS Diluted (Quarterly) | -0.24 |
| Enterprise Value | 12.28M |
| Earnings Yield | -45.59% |
| Normalized Earnings Yield | -159.59 |